Abstract:The development of the most successful cancer immunotherapies in solid tumors, immune-checkpoint blockade, has focused on factors regulating T-cell activation. Until recently, the field has maintained a predominately T-cell centric view of immunotherapy, leaving aside the impact of innate immunity and especially myeloid cells. Dendritic cells (DC) are dominant partners of T cells, necessary for initiation of adaptive immune responses. Emerging evidence supports a broader role for DCs in tumors including the maintenance and support of effector functions during T-cell responses. This relationship is evidenced by the association of activated DCs with immune-checkpoint blockade responses and transcriptional analysis of responding tumors demonstrating the presence of type I IFN transcripts and DC relevant chemokines. T-cell-inflamed tumors preferentially respond to immunotherapies compared with non–T-cell-inflamed tumors and this model suggests a potentially modifiable spectrum of tumor microenvironmental immunity. Although host and commensal factors may limit the T-cell-inflamed phenotype, tumor cell intrinsic factors are gaining prominence as therapeutic targets. For example, tumor WNT/β-catenin signaling inhibits production of chemokine gradients and blocking DC recruitment to tumors. Conversely, mechanisms of innate immune nucleic acid sensing, normally operative during pathogen response, may enhance DC accumulation and make tumors more susceptible to cancer immunotherapy. Elucidating mechanisms whereby DCs infiltrate and become activated within tumors may provide new opportunities for therapeutic intervention. Conceptually, this would facilitate conversion of non–T-cell-inflamed to T-cell-inflamed states or overcome secondary resistance mechanisms in T-cell-inflamed tumors, expanding the proportion of patients who benefit from cancer immunotherapy.

Chapter Three - Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

The role of dendritic cells in cancer immunity and therapeutic strategies

Dendritic cell subsets and implications for cancer immunotherapy

Dendritic cell biology and its role in tumor immunotherapy

Impaired function of dendritic cells within the tumor microenvironment

Dendritic cells as orchestrators of anticancer immunity and immunotherapy

Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

Dendritic Cells in Shaping Anti-Tumor T Cell Response

Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade

Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition

Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance

Dendritic Cells in Cancer Immunology and Immunotherapy

The Dendritic Cell-Tumor Cross-Talk in Cancer.

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

CCL19+ Dendritic Cells Potentiate Clinical Benefit of Anti-Pd-(l)1 Immunotherapy in Triple-Negative Breast Cancer

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects